PubMed Health⌕ Search

Biomedical subjects

W Diebschlag

Publications and source records attributed to W Diebschlag.

At least 19 recordsLinked to original sources
PubMed1996

Investigation of the therapeutic equivalence of different galenical preparations of O-(beta-hydroxyethyl)-rutosides following multiple dose peroral administration.

Oxerutins (O-(beta-hydroxyethyl)-rutosides, HR, Venoruton) are available in different releasing galenical formulations for the treatment of chronic venous insufficiency (CVI). In order to investigate the biopharmaceutical relevance of the releasing properties of the galenical forms the therapeutic efficacy between the commercially available forms was investigated (500 mg sustained release film tablets, 300 mg sustained release film tablets, 300 mg normally releasing capsules) in comparison to an aqueous solution and placebo. In total 100 female patients with CVI grade II participated. The study was carried out following a randomized, placebo controlled design with parallel treatment groups. Following a two-week run-in phase patients were treated for 12 weeks with different posologies of HR (2 x 1/d 500 mg, 3 x 1/d 300 mg, 1 x 1000 mg/d as aqueous solution). Main criterion was the reduction of leg volume following 12 weeks treatment. Subjective criteria were descriptively evaluated. All four HR treatments were significantly superior to placebo (p < 0.0008). The different posologies had no influence on the efficacy. The therapeutic efficacy is independent of the in vitro rate of release. The available forms are regarded as bioequivalent.

Aged↗
PubMed1993

Comparison between the efficacy and tolerability of oxerutins and troxerutin in the treatment of patients with chronic venous insufficiency.

Oxerutins (Venoruton) and troxerutin (CAS 7085-55-4) are both mixtures of O-(beta-hydroxyethyl)-rutosides used for the treatment of chronic venous insufficiency. As di-O-(beta-hydroxyethyl)-rutosides and 7-mono-O-(beta-hydroxyethyl)-rutoside were found to be more active with regard to free radical scavenging compared to tri-O-(beta-hydroxyethyl)-rutoside the aim of this study was to compare oxerutins and troxerutin clinically. 12 female, post-menopausal patients with chronic venous insufficiency grade II participated in this double-blind study with random allocation to the treatment groups. They received 900 mg/day oxerutins or troxerutin for 12 weeks and were observed for 4 further weeks without treatment. Leg volumes (water displacement) and subjective symptoms (VAS, visual analogue scale) were evaluated before and following 2, 4, 8, 12 and 16 weeks. Both treatments were active in reducing leg volumes and in ameliorating subjective symptoms (mean volume reduction -167 +/- 157 ml x week). Volume reduction totalled to -261 +/- 154.2 ml x week for oxerutins and -73.2 +/- 97.1 ml x week for troxerutin. The difference is statistically significant (p = 0.04). The findings with subjective symptoms were in good accordance to the objective volume measurement. Oxerutins revealed a remarkable carry over effect.

Anticoagulants↗
PubMed1993

Time course of the anti-oedematous effect of different dose regimens of O-(beta-hydroxyethyl) rutosides in healthy volunteers.

The aim of this study was to compare the efficacy of two posologies of hydroxyethylrutosides (HR) as maintenance dose for the reduction of leg oedema. The increase in leg volume induced by standing motionless for one hour was measured in 12 healthy young male volunteers by a highly sensitive water displacement method. The volume increase (approx. 87.8 units) was found to be very reproducible after a one-week placebo run-in period. The mean value after 3-weeks treatment at 1000 mg/day HR was reduced to 85.2 +/- 8.7 units. The subjects were then randomised to 3 groups and further measurements were made after additional 3, 5, 6 and 7 weeks. On placebo, the values returned to baseline within 5-6 weeks. On 500 mg/day, the values continued to oscillate around the values at randomisation (i.e., the effect was maintained). On continuing the dose unchanged at 1000 mg/day, the volume increases continued to fall progressively to 79.1 +/- 7.7 at the end of the further 7 weeks. After analysis of all mean volume changes relative to the values at time of randomisation, it was found that the 1000 mg/day dose showed a significant greater antioedematous effect than placebo (p = 0.0001) or 500 mg/day (p = 0.0028). Also the 500 mg/day dose was superior to placebo (p = 0.0328). We conclude that, after initial treatment for 3 weeks with 1000 mg/day, a dose of 500 mg/day is adequate to maintain the resultant anti-oedematous effect.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1992

[Treatment of acute ankle sprains. Comparison of the efficacy and tolerance of 2 indomethacin-gel preparations].

In a controlled randomized double-blind study, the effectiveness and tolerance of two gels containing the active substance indomethacin used in the treatment of acute sprains of the ankle were compared. Reduction in swelling and the evaluation of pain served as the criteria for the success of treatment. Over a treatment and observation period of two weeks, the parameters decreased rapidly and equally in both groups. At no time were statistically remarkable differences observed for any of the parameters. With respect to the main target parameter, the two preparations were seen to be of equal therapeutic effectiveness. Nor were there any differences in the tolerance of the two indomethacin gels.

Administration, Topical↗
PubMed1991

Time course of the anti-oedematous effect of O-(beta-hydroxyethyl)-rutosides in healthy volunteers.

O-(beta-hydroxyethyl)-rutosides (HR) is used for the treatment of disorders of the venous and microcirculatory systems. In order to evaluate the time course of its activity, the effect of HR on a provocation model of orthostatic oedema in healthy volunteers was used. After a 2 week placebo run-in period, 16 healthy volunteers were randomized to HR (2 tablets of 500 mg/day) of placebo for a further 3 weeks, in a double-blind parallel design. Oedema was provoked by standing motionless for 1 h, with measurement of leg volume before and afterwards. The procedure was undertaken at entry to the study and then weekly during the entire 5 week period. There were no significant differences in the extent of oedema produced by the orthostatic challenge during the 2 week run-in period or in the subjects who continued on placebo (approximately 90 arbitrary units i.e. approximately 48 ml). During the 3 week treatment with HR, however, there was a progressive reduction (-1.1, -5.9, and -7.6 arbitrary units after 1, 2, and 3 weeks, respectively) in the volume of induced oedema, which was significant after 2 and 3 weeks of treatment compared to the placebo group.

Adult↗
PubMed1990

A double-blind study of the efficacy of topical ketorolac tromethamine gel in the treatment of ankle sprain, in comparison to placebo and etofenamate.

In a double-blind, placebo-controlled study the efficacy and safety of topical ketorolac tromethamine were assessed in the reduction of inflammation and pain due to ankle sprain. Ketorolac 2% gel was compared with etofenamate and placebo (ketorolac vehicle) in a 15-day study. Patients attended for visits on days 1 (admission), 2, 3, 4, 8, and 15 of the study. Measurements of efficacy were ankle volume, pain measured on visual analogue scales (VAS) and verbal rating of pain. Safety was assessed by volunteered adverse events and vital signs. A total of 37 patients was admitted to the study of whom 13 received ketorolac, 12 placebo, and 12 etofenamate. One patient receiving ketorolac was lost to follow-up on day 15 owing to an unrelated accident. The remaining 36 patients completed the study. Ketorolac was significantly better than placebo in reducing the volume of the injured ankle based on the maximum, the area under the curve, and the day 15 percentage changes in ankle volume. Results for etofenamate were similar to those for ketorolac for all three variables and there were no significant differences between the active treatments. Reductions in VAS pain at rest were more marked in the ketorolac group than either of the other groups at all visits. On day 4 the differences between ketorolac and each of the other groups were statistically significant. Reductions in VAS pain on movement were also greatest for the ketorolac group at all visits. The differences between ketorolac and each of the other groups achieved statistical significance on days 4 and 8, but were marginal in terms of significance on day 2.(ABSTRACT TRUNCATED AT 250 WORDS)

Acetaminophen↗
PubMed1990

[Computer-assisted analysis of pressure distribution on cattle claws].

A newly developed measuring device was applied to quantify in 5 first and 5 second lactation cows of the breed German Black and White the pressure distribution underneath the claws of one front limb. The pressure distribution of cows was recorded five times in intervals of four weeks. At each measuring date each had to undergo three tests. Procedures for image processing were applied in analysis of pressure distributions. The average pressure per sqcm was about 19 N, the maximum pressure measured was 59 N per sqcm in first lactating cows and 56 N per sqcm in second lactation cows. Factors were developed which characterize the patterns of pressure distributions. Especially the "gradient factor" seems to be well suited to recognize inhomogeneous pressure distributions.

Animals↗
PubMed1989

[A 3-month, randomized double-blind dose-response study with 0-(beta-hydroxyethyl)-rutoside oral solutions].

The antioedematous effect of 0-(beta-Hydroxylethyl)-rutoside (HR)-drinking solutions with 600, 900, 1200 and 1500 mg active substance was tested in a randomized double-blind study against placebo with 30 female patients in the change of life. The decrease of the oedemas was measured by recording the change in the leg volume. The patients valued the symptoms "tired and heavy legs", "tenseness" and "tingling sensation". After 3 months the daily taking of HR-drinking solutions showed a significant decrease of leg volume. At the end of the treatment there was no significant difference between the four verum groups.

Administration, Oral↗
PubMed1987

[Improving seating comfort in wheelchairs for the prevention of pressure sores].

The risk factors for occurrence of pressure sores--pressure, temperature and humidity--were measured in extensive tests on commercially available wheelchair designs. The effects of different chair positions on the strain and pressure distribution on the backrest, seat surface and foot rests were recorded on a universally adjustable experimental chair. In order to appraise the influence of various types of handicaps, the experiments were conducted with paraplegic, spastic and hemiplegic subjects. It became evident from the results obtained that the currently used suspension belt chairs display serious deficiencies, inherent in their construction principle. Above all, they do not offer an adequately large support area to handicapped persons with severe atrophy of the gluteal muscle. Also, a backrest shape with lumbar pad, as requested by physiologists and orthopaedic surgeons, is technically difficult to realize. Considerable improvements with respect to pressure distribution and orthopaedically correct support of the seated patient can be achieved by using a shell seat construction. In order to enable the handicapped person to use various sitting postures, the backrest should be provided with a rotary joint to the sitting surface.

Persons with Disabilities↗
PubMed1987

[The effect of topical treatment in the treatment of disease in ankle sprains].

The efficacy of Mobilat ointment (100 g contain: Extract. suprarenale 1.0 g, Mucopolysaccharide-polysulfate 0.2 g, salicylic acid 2.0 g) in the treatment of acute lateral distortions of the ankle was tested in a randomised, placebo-controlled, double blind study. The criteria used for the assessment of the progress of healing were the pressure distribution during walking, the swelling of the injured region and the evaluation of pain using a visual analogue scale. During the period of treatment and observation lasting 2 weeks, all the assessment criteria showed a more rapid regression in the symptoms and signs of the disorder on treatment with the active product. The differences were statistically significant for all the criteria assessed.

Administration, Topical↗
PubMed1985

Benzydamine cream in post-traumatic oedema.

The therapeutical effect of drugs for ankle distortions was quantified by a volumetric method and by load distribution during walking. The results obtained were comparable and showed that 5% benzydamine cream was very effective in the reduction of oedema of post-traumatic origin.

Administration, Topical↗